Phase I/II study of CT-2103 (Xyotax) in patients with recurrent ovarian cancer

被引：0
|
作者：
Sabbatini, P
Brown, J
Peters, WA
Jacobs, A
Mehdi, A
Crozier, MA
Rivkin, S
Bolton, MG
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, New York, NY 10021 USA
[2] Gynecol Oncol Associates, Dept Med Oncol, Newport Beach, CA USA
[3] Pacific Gynecol Specialists, Dept Med Oncol, Seattle, WA USA
[4] Virginia Mason Med Ctr, Dept Med Oncol, Seattle, WA 98101 USA
[5] Stockton Hematol Oncol Med Grp, Dept Med Oncol, Stockton, CA USA
[6] SW Reg Canc Ctr, Dept Med Oncol, Austin, TX USA
[7] Swedish Med Ctr & Tumor Inst, Dept Med Oncol, Seattle, WA USA
[8] Cell Therapeut Inc, Clin Dev, Seattle, WA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
430
引用
收藏
页码：S130 / S130
页数：1
相关论文
共 50 条
  • [21] Phase II study of trabectedin in pretreated patients with recurrent epithelial ovarian cancer (REOC)
    Marinaccio, Marco
    Mele, Emilia
    Lorusso, Vito
    Fumarulo, Valeria Vincenza
    Sozzi, Fausta
    Cicinelli, Ettore
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] A phase II study of biweekly administration of paclitaxel in patients with recurrent epithelial ovarian cancer
    Lorenz, E
    Hagen, B
    Himmelmann, A
    Kjorstadt, K
    Onsrud, M
    Tingulstad, S
    Gundersen, G
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1999, 9 (05) : 373 - 376
  • [23] Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer
    Levy, T
    Inbar, M
    Menczer, J
    Grisaru, D
    Glezerman, M
    Safra, T
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 686 - 690
  • [24] A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer
    Takeuchi, Satoshi
    Shoji, Tadahiro
    Kagabu, Masahiro
    Honda, Tatsuya
    Miura, Fumiharu
    Omi, Hideo
    Takada, Anna
    Sugiyama, Toru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] A phase I/II study of topotecan in combination with Carboplatin in recurrent epithelial ovarian cancer.
    Scarfone, G
    Parazzini, F
    Sciatta, C
    Polverino, GP
    Rosa, C
    Guarnerio, P
    Bolis, G
    ANNALS OF ONCOLOGY, 2000, 11 : 86 - 86
  • [26] A phase I/II study of pemetrexed in combination with carboplatin in patients with platin sensitive recurrent ovarian or peritoneal cancer (PSOC)
    Sehouli, J.
    Kania, M.
    Zimmerman, A.
    Look, K.
    Mustea, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] A phase I/II study of carboplatin and paclitaxel in patients with epithelial ovarian cancer
    Yamamoto, R
    Minobe, S
    Kaneuchi, M
    Sakuragi, N
    Fujimoto, S
    Ishizaki, Y
    Domon, H
    Hareyama, H
    Sato, C
    Fujino, T
    Kawaguchi, I
    Yamaguchi, T
    Fujimoto, T
    Yoshiaki, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2002, 32 (04) : 128 - 134
  • [28] Phase II study of first-line chemotherapy using CT-2103 in patients with non-small-cell lung cancer who are > or = 70 years of age or who have PS = 2
    Neubauer, MA
    Harper, HH
    Miller, G
    Infortuno, J
    Paradise, C
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S130 - S130
  • [29] Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX™], a biodegradable polymeric drug conjugate -: Characterization, preclinical pharmacology, and preliminary clinical data
    Singer, JW
    Baker, B
    De Vries, P
    Kumar, A
    Shaffer, S
    Vawter, E
    Bolton, M
    Garzone, P
    POLYMER DRUGS IN THE CLINICAL STAGE: ADVANTAGES AND PROSPECTS, 2003, 519 : 81 - 99
  • [30] A phase II evaluation of temozolomide in patients with recurrent epithelial ovarian cancer
    Judson, PL
    Harkness, CB
    Boente, MP
    Downs, LS
    Argenta, PA
    Carson, LF
    GYNECOLOGIC ONCOLOGY, 2004, 93 (03) : 667 - 670
12345